当前位置: 首页 >> 检索结果
1649. Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial.
作者: Steven E Nissen.;Qiuqing Wang.;Stephen J Nicholls.;Ann Marie Navar.;Kausik K Ray.;Gregory G Schwartz.;Michael Szarek.;Erik S G Stroes.;Roland Troquay.;Jannick A N Dorresteijn.;Henry Fok.;David A Rider.;Steven Romano.;Kathy Wolski.;Curtis Rambaran.
来源: JAMA. 2024年332卷23期1992-2002页
Elevated lipoprotein(a) increases the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis.
1650. Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial.
作者: Stephen J Nicholls.;Wei Ni.;Grace M Rhodes.;Steven E Nissen.;Ann Marie Navar.;Laura F Michael.;Axel Haupt.;John H Krege.
来源: JAMA. 2025年333卷3期222-231页
Muvalaplin inhibits lipoprotein(a) formation. A 14-day phase 1 study demonstrated that muvalaplin was well tolerated and reduced lipoprotein(a) levels up to 65%. The effect of longer administration of muvalaplin on lipoprotein(a) levels in individuals at high cardiovascular risk remains uncertain.
1652. Pulmonary Vein Isolation With Optimized Linear Ablation vs Pulmonary Vein Isolation Alone for Persistent AF: The PROMPT-AF Randomized Clinical Trial.
作者: Caihua Sang.;Qiang Liu.;Yiwei Lai.;Shijun Xia.;Ruhong Jiang.;Songnan Li.;Qi Guo.;Qifan Li.;Mingyang Gao.;Xueyuan Guo.;Lihong Huang.;Nian Liu.;Chenxi Jiang.;Song Zuo.;Xiaoxia Liu.;Mengmeng Li.;Weili Ge.;Shangming Song.;Lianghua Chen.;Shuanglun Xie.;Jiangang Zou.;Ke Chen.;Xiangfei Liu.;Hesheng Hu.;Xinhua Wang.;Jinlin Zhang.;Zhaojun Wang.;Chi Wang.;Liu He.;Chao Jiang.;Ribo Tang.;Ning Zhou.;Yunlong Wang.;Deyong Long.;Xin Du.;Chenyang Jiang.;Laurent Macle.;Jianzeng Dong.;Changsheng Ma.; .
来源: JAMA. 2025年333卷5期381-389页
Success rates of pulmonary vein isolation (PVI) are modest for persistent atrial fibrillation (AF). Additional linear ablation beyond PVI has not been proved superior to PVI alone in randomized trials. Ethanol infusion of the vein of Marshall (EIVOM) facilitates ablation at the mitral isthmus and may lead to improved effectiveness of a linear ablation strategy.
1655. Diagnosis and Treatment of Polycythemia Vera: A Review.
作者: Douglas Tremblay.;Marina Kremyanskaya.;John Mascarenhas.;Ronald Hoffman.
来源: JAMA. 2025年333卷2期153-160页
Polycythemia vera (PV), a myeloproliferative neoplasm characterized by an increased red blood cell mass and increased risk of thrombosis, affects approximately 65 000 people in the US, with an annual incidence of 0.5 to 4.0 cases per 100 000 persons.
1660. Evaluating Performance and Agreement of Coronary Heart Disease Polygenic Risk Scores.
作者: Sarah A Abramowitz.;Kristin Boulier.;Karl Keat.;Katie M Cardone.;Manu Shivakumar.;John DePaolo.;Renae Judy.;Francisca Bermudez.;Nour Mimouni.;Christopher Neylan.;Dokyoon Kim.;Daniel J Rader.;Marylyn D Ritchie.;Benjamin F Voight.;Bogdan Pasaniuc.;Michael G Levin.;Scott M Damrauer.; .
来源: JAMA. 2025年333卷1期60-70页
Polygenic risk scores (PRSs) for coronary heart disease (CHD) are a growing clinical and commercial reality. Whether existing scores provide similar individual-level assessments of disease susceptibility remains incompletely characterized.
|